TEL AVIV, ISRAEL / VANCOUVER, CANADA, JANUARY 31, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”) Treatment , a biotechnology company focused on discovering and developing new psychedelic-derived therapeutics to solve major underserved health problems, today announced a collaboration with Professor Gal Yadid of Bar-Ilan University and Gonda Multidisciplinary in Israel. As part of the ongoing collaboration, a new preclinical trial (the “Trial”), the Center for Brain Research, has yielded positive results for the treatment of Major Depressive Disorder (“MDD”).
This study evaluated 2-fluorodeschloroketamine (“2-FDCK”), an innovative analogue of ketamine. This is our patent pending in the US Patent and Trademark Office and is used to treat depression, including treatment-resistant depression.
The aim of this trial is to determine the effects of 2-FDCK on motivational state in rodents as a treatment for depressive behavior and to test 2-FDCK as a potential novel long-term pharmacological psychoactive treatment for MDD. That was it. In this study, Flinders Sensitive Line (“FSL”) rats, an animal model of depression, were treated with either ketamine or his 2-FDCK for 14 consecutive days.
The results indicate that it is likely to safely treat both acute and chronic depression compared to ketamine, which is currently used to treat depression. suggesting superior effects of 2-FDCK versus ketamine on depressive-like behavior. Both ketamine and 2-FDCK affected depressive-like symptoms. However, using a chronic treatment paradigm, only 2-FDCK had long-lasting effects.
“One of our goals, working closely with leading researchers around the world, is to investigate unique compounds as new and innovative treatments for addiction and mental health disorders,” said CEO of Clearmind. Adi Zuloff-Shani, Ph.D., has treatment-resistant depression with limited options available.”
About Clearmind Medicine
Clearmind is a psychedelic pharmaceutical biotechnology company focused on the discovery and development of new psychedelic-derived therapeutics to solve a wide range of underserved health problems, including alcohol use disorders. I guess. Its primary purpose is to research and develop psychedelic-based compounds and commercialize them as regulated drugs, foods, or supplements.
The company’s intellectual portfolio currently consists of seven patent families. The company intends to seek additional patents for its compounds whenever warranted, and remains opportunistic in acquiring additional intellectual property to build its portfolio.
Clearmind shares are listed on the Nasdaq and Canadian Stock Exchanges under the symbol “CMND” and on the Frankfurt Stock Exchange under the symbol “CWY”.
See below for more information. https://www.clearmindmedicine.com or contact:
Phone: (604) 260-1566
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expect”, “expect”, “intend”, “plan”, “believe”, “seek”, “estimate” and similar expressions or variations of such words are It is intended to identify forward-looking statements. For example, we use forward-looking statements when discussing the results of preclinical studies, the conduct of future studies, the results of future projects and the filing of patent applications. state of mental health. Forward-looking statements are based on management’s current expectations, beliefs and projections rather than historical facts, many of which are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from those expressed or indicated in the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For more information on the risks and uncertainties that affect us, please refer to our reports filed from time to time with the U.S. Securities and Exchange Commission (“SEC”). The company’s final prospectus filed with the SEC on November 16, 2022 (registration number 333-265900). To reflect changes in actual results, subsequent events or circumstances, changes in assumptions, or other factors affecting forward-looking information, except to the extent required by applicable securities laws. does not undertake any obligation to update any forward-looking statements. Even if we update one or more forward-looking statements, no inference should be taken that we will make additional updates with respect to it or any other forward-looking statement. References and links to websites are provided as a convenience, and information contained in such websites is not incorporated by reference into this press release. Clearmind is not responsible for the content of third party websites.